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Background/Aims
The aim of this study was to compare the efficacy and tolerability of topiramate and propranolol in preventing pediatric cyclic 
vomiting syndrome. 
Methods
A retrospective medical-record review of patients who underwent prophylaxis after receiving a diagnosis of cyclic vomiting syndrome 
was performed. Patients who completed at least 12 months of treatment were included in the analysis. Responder rate, and adverse-
event rates were also calculated from all patients. Response to treatment was assessed as the total number of vomiting attacks 
per year. Patients in whom the frequency of vomiting attack reduced greater or equal to 50% were defined as responders, and the 
remaining patients were classified as nonresponders. 
Results
A total of 38 patients who were treated prophylactically with either topiramate (16 patients) or propranolol (22 patients) were 
identified. Fifty-nine percent of the patients in the propranolol group and 81% of the patients in the topiramate group reported 
freedom from attacks. A decrease of more than 50% in attacks per year occurred in 23% of patients in the propranolol group and 
13% of patients in the topiramate group. The responder rates were 81% for propranolol group and 94% for topiramate group (P = 
0.001). Despite minor adverse effects (drowsiness, nervousness, and dizziness) observed in a few patients, the adverse event rates 
were not significantly different between the 2 groups (P = 0.240). 
Conclusions
The efficacy of topiramate was superior to propranolol for the prophylaxis of pediatric cyclic vomiting syndrome. 
(J Neurogastroenterol Motil 2016;22:656-660)
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Introduction  
Cyclic vomiting syndrome (CVS) is a disease characterized 
by recurrent episodes of incapacitating nausea and vomiting in-
terspersed with relatively symptom-free intervals that might last 
anywhere from a few days to several months.1 Emesis is most in-
tense and frequent within the first hour with a median frequency 
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of 6 times/hour and it declines within 4-8 hours with the entire 
episode lasting on average between 2 and 3 days, although it may be 
longer (5-45 days). Other symptoms and signs commonly include 
abdominal pain in 80%, headache or migraine in about 40%, and 
nearly all children have pallor and fatigue.2 The prevalence of CVS 
in the pediatric population ranges from 0.3% to 15%, depending on 
the study population and design.3,4
CVS is generally believed to be a variant of migraine and the 
diagnosis is made by exclusion of other organic diseases.5 The pos-
sible etiologies have ranged from sympathetic and parasympathetic 
dysfunction, and stress/anxiety/depression.6 Treatment during the 
vomiting phase has the goals to prevent dehydration and to ter-
minate the cycles of nausea, vomiting and abdominal pain. This 
involves rehydration, electrolyte and nutritional management, and 
antiemetic, antianxiety and/or analgesic medications.7 Prophylac-
tic treatment is proposed to prevent recurrent episodes, abortive 
treatment and/or supportive care to ameliorate acute episodes.1,2,7 
Preventive treatment with tricyclic antidepressants, β-adrenoceptor 
antagonists (propranolol) or cyproheptadine have been shown to 
be safe and effective in pediatric patients with CVS.8-10 Also, drugs 
such as pizotifen, erythromycin, coenzyme Q10, and antiepileptics 
including valproate, phenobarbital, and topiramate can be used 
for CVS prophylaxis.11-15 Topiramate, an antiepileptic medication, 
has been used with increasing frequency in the treatment of non-
epileptic periodic anomalies including headaches, abdominal mi-
graine, and CVS. Few studies have been conducted to establish the 
efficacy of topiramate in childhood CVS. Ölmez et al16 reported a 
child with CVS whose symptoms resolved with topiramate. Boles12 
reported 2 children with CVS, who were refractory to amitriptyline 
and cyproheptadine, and were succesfully treated with topiramate. 
Finally, in a last study, Kumar et al17 reported a response rate of 60% 
for topiramate in 30 patients with CVS. Propranolol is one of the 
most common and effective drug of choice for CVS.2,7,18 However, 
no study has compared topiramate with propranolol as a prophylac-
tic treatment of pediatric CVS in real clinical practice settings. The 
purpose of this study was to perform a comparison of propranolol 
and topiramate in pediatric CVS.
Materials and Methods  
Using our patient database, pediatric patients, aged < 18 years, 
diagnosed with CVS and received a minimum of 12 months of 
therapy with either topiramate or propranolol were identified. Ex-
clusion criteria were, the presence of gastrointestinal, neurological, 
or inherited metabolic diseases and the previous use of any drugs 
for the treatment of CVS including propranolol or topiramate. 
The diagnosis of CVS was established based on the International 
Headache Society 2004 Classification19 and Rome III criteria.7 The 
baseline investigations performed on all CVS patients at the time of 
diagnosis in our departments included: complete blood count, liver 
function tests, creatinine, blood urea nitrogen, electrolytes, lipid 
profile, antinuclear antibody, lactate, pyruvate, ammonia, plasma 
amino acid, acylcarnitine profile, urine organic acid analysis, electro-
encephalogram, and abdominal ultrasonography. The starting dose 
of propranolol was 1 mg/kg/day, taken once and at night and the 
decision to increase the dose was also made after 1 month of treat-
ment. The initial dose of topiramate was 25 mg as a single nightly 
dose, and this dose was slowly increased to a maximum of 75 mg/
day until efficay was achieved.
Thirty-eight parents were sent a questionnaire asking questions 
pertaining to their perceived efficacy and tolerability of their child’s 
experience with topiramate and propranolol. They were specifically 
asked to report the average number of attacks per year, duration of 
cycles (in hour), episodes of vomiting (per cycle), peak number of 
emesis (per hour) experienced, and also all adverse events during 
treatment. 
Clinical follow-up information, regarding sex, age at diagnosis, 
duration and efficacy of treatment, and any adverse events were 
retrieved. Patients in whom the frequency of vomiting attacks were 
reduced by greater or equal to 50% were defined as responders, and 
the remaining patients were classified as nonresponders. Patients 
were considered as attack free if they did not have any attack for at 
least 1 year. The rate of adverse events and their profiles were also 
compared. 
Statistical Methods
This study was approved by the Institutional Ethics Commit-
tee of our hospital (IRB number:2010/28B), and all patients’ legal 
guardians gave informed consent prior to entering the study.
Statistical analysis was performed using SPSS 18.0 for Win-
dows. To compare patient characteristics, Student’s t test was used 
for continuous variables. Fisher’s exact test was used for the analysis 
of discrete variables based on sample size. A P < 0.05 was consid-
ered significant. 
Results  
A total of 38 pediatric patients (16 males and 22 females) who 
were treated prophylactically with either topiramate or propranolol 
were identified. Topiramate was prescribed to 16 patients (5 males 
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and 11 females) and propranolol was prescribed to 22 patients (10 
males and 12 females). Subject age at the time of diagnosis ranged 
from 8 years to 14 years (11.4 ± 2.1 years) in the topiramate group 
and 9 years to 15 years (12.6 ± 1.8 years) in the propranolol group. 
The mean age at the time of treatment did not differ significantly 
between the 2 groups (P = 0.360) (Table). 
The doses of topiramate among the responders ranged between 
25 mg and 75 mg per day. Of the responders, the final topiramate 
dose was 25 mg in 14 patients, 50 mg in 1 patient, and 75 mg in 
1 patient. The final maintenance dose of propranolol was 1.4 mg/
kg/day (5/22 patients). Treatment duration was shorter for the pro-
pranolol group (16.8 ± 2.2 months vs 17.5 ± 3.4 months); how-
ever, this difference was not significant (P = 0.150).
 The distribution and outcomes after the prophylactic treatment 
Table. Demographic and Clinical Data of Subjects.
Variables
Propranolol 
(n = 22)
Topiramate 
(n = 16)
P-value
Age at diagnosis (yr) 12.6 ± 1.8 11.4 ± 2.1 0.360
Sex (male/female) 10/12 5/11 0.050
Treatment duration (mo) 17.5 ± 3.4 16.8 ± 2.2 0.150
Parameters before treatment
    Attack numbers per yr
    Median duration of cycles in hr
    Episodes of vomiting per cycle
    Peak number of emesis per hr 
4.0 ± 0.6
19.0 ± 4.3
15.0 ± 3.1
6.0 ± 0.1
5.0 ± 0.1
17.0 ± 5.1
14.0 ± 2.3
5.0 ± 0.2
0.370
0.060
0.040
0.050
Parameters after treatment period 
    Attack numbers per yr
    Median duration of cycles in hr
    Episodes of vomiting per cycle
    Peak number of emesis per hr
2.0 ± 0.6
15.0 ± 1.4
15.0 ± 1.8
5.0 ± 0.1
1.0 ± 0.4
11.0 ± 2.2
12.0 ± 1.4
3.0 ± 0.3
0.040
0.001
0.050
0.040
Response to treatment
    Attack free  
    ≥ 50% decrease
    < 50% decrease or no change
 59% (13/22)
23% (5/22)
18% (4/22)
 81% (13/16)
13% (2/16)
 6% (1/16)
0.050
0.110
0.001
Adverse events (%)  14% (3/22) 12% (2/16) 0.240
    Drowsiness
    Nervousness
    Dizziness
1
1
1
1
-
1
Mean weight change from baseline (kg) 0.8 ± 0.3 (2.3%) −1.1 ± 0.5 (2.9%) 0.320
Data are expressed as mean ± SD.
P < 0.05 is statistically significant.
Cyclic vomiting syndrome (n = 38)
Propranolol treatment (n = 22) Topiramate treatment (n = 16)
Responder
(n = 18)
Non-responder
(n = 4)
Responder
(n = 15)
Non-responder
(n = 1)
Figure. Diagram showing the distribu-
tion and outcomes after the prophylactic 
treatment for cyclic vomiting syndrome.
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for CVS are described in the Figure. After 12 months of treat-
ment, 59% of the patients in the propranolol group and 81% of the 
patients in the topiramate group reported freedom from attacks. A 
decrease of more than 50% in attacks per year occurred in 23% of 
patients in the propranolol group and 13% of patients in the topi-
ramate group. The responder rates were 82% for propranolol and 
94% for topiramate (P = 0.001) (Table). 
The average number of attacks per year, duration of cycles (in 
hour), episodes of vomiting (per cycle), and peak number of emesis 
(per hour) before and after the treatment period in either treatment 
group are described in the Table.
Four patients who were non-responsive to propranolol were 
treated with topiramate, and all of them had a satisfactory response. 
One patient who was non-responsive to topiramate was also non-
responsive to other medications as well including propranolol, ami-
triptyline and cyproheptadine. 
The analysis revealed no statistically significant differences be-
tween the 2 groups for treatment related adverse effects (P = 0.150). 
In the topiramate group, 2 patients experienced mild adverse effects, 
which were drowsiness and dizziness. In the propranolol group, 3 
patients experienced treatment related adverse effects that included 
drowsiness, nervousness, and dizziness. No dropouts occurred in 
our study due to adverse effects. Mean baseline body weight was 
37 ± 4.2 kg in the topiramate group and 35 ± 2.1 kg in the pro-
pranolol group. In the topiramate group, the mean weight loss after 
the end of 12 months was 1.1 ± 0.5 kg (2.9%). In the propranolol 
group, the mean weight gain after the end of 12 months was 0.8 ± 
0.3 kg (2.3%). 
Finally, none of the study participants had a history of migraine 
or had any electroencephalographic abnormalities.
Discussion  
Although several preventive agents have been demonstrated to 
be helpful, the treatment of CVS in children is difficult, and it takes 
several months to achieve effective relief. Tricyclic antidepressants 
like amitriptyline, antihypertensives like propranolol, and anticon-
vulsants such as valproate, phenobarbital and topiramate have been 
shown to be effective to prevent CVS in several studies.9-15 In our 
study, we compared the efficacy and safety of propranolol and topi-
ramate in preventing pediatric CVS.
A β-adrenoceptor antagonist propranolol is recommended as 
a prophylactic drug in children with CVS of all ages. Aanpreung 
and Vajaradul20 compared amitriptyline, propranolol and pizotifen 
in pediatric CVS patients and they reported 61%, 50%, and 50% 
response rates, respectively. In a study conducted on 14 pediatric 
CVS patients, a 67% response rate to propranolol was reported.9 In 
a last and retrospective study of 181 children with CVS, Haghighat 
et al15 reported that propranolol was significantly more effective 
than amitriptyline (92% vs 56%) with a follow-up period ranging 
from 6 months to 12 years. In our study, 82% of the patients in the 
propranolol group responded to propranolol therapy.
Anticonvulsants, including phenobarbital, valproate, leveti-
racetam and topiramate, are also increasingly being used in the 
treatment of CVS. Topiramate has a number of physiologic effects 
that may play a role in CVS prevention, including blocking voltage-
dependent sodium channels, and augmenting the activity of the 
neurotransmitter gamma-aminobutyrate at some subtypes of the 
gamma-aminobutyric acid class A receptor.21 Among few studies 
investigating the effects of topiramate in CVS, Ölmez et al16 re-
ported a child having CVS with generalized epileptiform discharges 
who responded to topiramate therapy. In a last large single center 
study, Kumar et al.17 retrospectivly reviewed the clinical features 
of 101 pediatric-onset and adult-onset patients with CVS. In their 
study, the responder rate was reported to be 60% with topiramate. 
In our study, the response rate for topiramate was 94%. Our results 
were inconsistent with the findings of Kumar et al17. A possible 
explanation for the higher responser rate might be associated with 
lower mean ages of our patients. To our knowledge, this is the first 
study to compare the efficacy of propranolol and topiramate for 
CVS prophylaxis in pediatric patients. The results of our study 
show that topiramate was superior to propranolol for the manage-
ment of CVS.
The gender split is 23-58% male and 42-86% female in pediat-
ric CVS patients.1-4 In our study, male patients were more frequent 
in the propranolol group. The effect of sex difference on response to 
treatment has not been investigated in previously published studies. 
Therefore, male predominance in the propranolol group might not 
affect the treatment outcomes in our study. 
The most frequently reported adverse effects related to pro-
pranolol or topiramate included restlessness, sleep disturbance, 
asthenia, dizziness, somnolence, ataxia, tremors, dysarthria, blurred 
vision, gastrointestinal symptoms, and weight loss.16,17,22 In the pres-
ent study, the most commonly observed side effects in both groups 
included drowsiness, nervousness and dizziness. Weight loss due to 
appetite decrease is a frequent side effect of topiramate. In our study, 
we observed only mild weight loss (2.9% of initial body weight) on 
topiramate. 
As the side effects can be minimized by increasing the dose 
slowly, topiramate was administered at the lowest dose effective. In 
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our study, the responder criteria at 25 mg/day was achieved by all 
the responders, except two, in the topiramate group.
One of the most important limitation is the retrospective nature 
of the study. Although the 12-months treatment period was shorter 
and the size of the sample was smaller than many studies on CVS, 
we found that topiramate appeared to be more effective than pro-
pranolol in the prophylaxis of CVS.
In conclusion, the efficacy of topiramate was superior to that of 
propranolol for pediatric CVS. Adverse effect rates did not differ 
between the treatment groups. Further open- label and controlled 
trials with larger sample sizes, longer treatment periods and ad-
ditional test drugs should be conducted on investigating optimal 
treatment in pediatric CVS. 
Financial support: None.
Conflicts of interest: None.
Author contributions: Oya B Sezer: substantial contributions 
to the conception and design, the acquisition, analysis, or interpre-
tation of the data; Taner Sezer: final approval of the version to be 
published; and all authors: drafting of the article or critical revision 
for important intellectual content.
References  
1. Abell TL, Adams KA, Boles RG, et al. Cyclic vomiting syndrome in 
adults. Neurogastroenterol Motil 2008;20:269-284. 
2. Yang HR. Recent concepts on cyclic vomiting syndrome in children. J 
Neurogastroenterol Motil 2010;16:139-147.
3. Ertekin V, Selimoglu MA, Altnkaynak S. Prevalence of cyclic vomiting 
syndrome in a sample of Turkish school children in an urban area. J Clin 
Gastroenterol 2006;40:896-898.
4. Fitzpatrick E, Bourke B, Drumm B, Rowland M. The incidence of 
cyclic vomiting syndrome in children: population-based study. Am J Gas-
troenterol 2008;103:991-995.
5. Drossman DA. The functional gastrointestinal disorders and the Rome 
III process. Gastroenterology 2006;130:1377-1390.
6. Hejazi RA, Lavenbarg TH, Pasnoor M, et al. Autonomic nerve func-
tion in adult patients with cyclic vomiting syndrome. Neurogastroenterol 
Motil 2011;23:439-443.
7. Li BU, Lefevre F, Chelimsky GG, et al. North American Society for Pe-
diatric Gastroenterology, Hepatology, and Nutrition consensus statement 
on the diagnosis and management of cyclic vomiting syndrome. J Pediatr 
Gastroenterol Nutr 2008;47:379-393.
8. Forbes D, Withers G. Prophylactic therapy in cyclic vomiting syndrome. 
J Pediatr Gastroenterol Nutr 1995;21(suppl1):S57-S59.
9. Andersen JM, Sugerman KS, Lockhart JR, Weinberg WA. Effective 
prophylactic therapy for cyclic vomiting syndrome in children using ami-
triptyline or cyproheptadine. Pediatrics 1997;100:977-981. 
10. Ghosh JB, Roy M, Peters T. Cyclic vomiting syndrome responding to 
amitryptiline. Indian J Pediatr 2009;76:1261-1262.
11. Vanderhoof JA, Young R, Kaufman SS, et al. Treatment of cyclic vom-
iting in childhood with erythromycin. J Pediatr Gastroenterol Nutr 
1995;21(suppl1):S60-S62. 
12. Boles RG. High degree of efficacy in the treatment of cyclic vomiting 
syndrome with combined co-enzyme Q10, L-carnitine and amitriptyline, 
a case series. BMC Neurol 2011;11;102. 
13. Gokhale R, Huttenlocher PR, Brady L, Kirschner BS. Use of barbi-
turates in the treatment of cyclic vomiting during childhood. J Pediatr 
Gastroenterol Nutr 1997;25:64-67. 
14. Hikita T, Kodama H, Nakamoto N, et al. Effective prophylactic therapy 
for cyclic vomiting syndrome in children using valproate. Brain Dev 
2009;31:411-413.
15. Haghighat M, Rafie SM, Dehghani SM, Fallahi GH, Nejabat M. 
Cyclic vomiting syndrome in children: experience with 181 cases from 
southern Iran. World J Gastroenterol 2007;13:1833-1836.
16. Olmez A, Köse G, Turanli G. Cyclic vomiting with generalized epi-
leptiform discharges responsive to topiramate therapy. Pediatr Neurol 
2006;35:348-351.
17. Kumar N, Bashar Q, Reddy N, et al. Cyclic vomiting syndrome (CVS): 
is there a difference based on onset of symptoms--pediatric versus adult? 
BMC Gastroenterol 2012;12:52.
18. Yang HR, Ko JS, Seo JK. A Study on the disease course and prognosis of 
cyclic vomiting syndrome. J Korean Pediatr Soc 2001;44:1141-1156.
19. Headache Classification Subcommittee of the International Headache 
Society. The international classification of headache disorders, 2nd ed. 
Cephalalgia 2004;24(suppl 1):S1-S160. 
20. Aanpreung P, Vajaradul C. Cyclic vomiting syndrome in Thai children. J 
Med Assoc Thai 2002;85(suppl 2):S743-S748. 
21. Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at 
GABAA receptors. Seizure 2013;22:589-600.
22. Garg KC, Singhal KC, Kumar S, Lal A. Adverse reactions to proprano-
lol, a non-selective beta-adrenergic blocking agent in hypertensive pa-
tients–a collaborative study. Indian J Physiol Pharmacol 1993;37:67-70.
